biostudies-literatureLi TThe Haiyan Fund ProjectNational Natural Science Foundation of ChinaPostgraduate Research &amp; Practice Innovation Program of Harbin Medical Universitye010534https://www.ebi.ac.uk/biostudies/studies/S-EPMC11590841biostudies-literatureUnknown12(11)<h4>Background</h4>Despite the success of immune checkpoint inhibitor (ICI)-based combination therapies in hepatocellular carcinoma (HCC), its effectiveness remains confined to a subset of patients. The development of reliable, predictive markers is important for accurate patient stratification and further mechanistic understanding of therapy response.<h4>Methods</h4>We comprehensively analyzed paired single-cell RNA transcriptome and T-cell repertoire profiles from 14 HCC ascites samples, collected from 7 patients before and after treatment with the combination of sintilimab (anti-PD-1) and bevacizumab (anti-VEGF).<h4>Results</h4>We identify a widespread convergence on interferon (IFN) signaling across various immune cell lineages in treatment-responsive patients with HCC, indicating a coJournal for immunotherapy of cancerIntegrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy.PMC115908418227349282394454YJSCX2024-12HYDJJMS2023-01Hou ZXu CZhang MKong DWang GGuo SLyu CXu HLi XLi TRen JLiu CHao DfalseIntegrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy.<h4>Background</h4>Despite the success of immune checkpoint inhibitor (ICI)-based combination therapies in hepatocellular carcinoma (HCC), its effectiveness remains confined to a subset of patients. The development of reliable, predictive markers is important for accurate patient stratification and further mechanistic understanding of therapy response.<h4>Methods</h4>We comprehensively analyzed paired single-cell RNA transcriptome and T-cell repertoire profiles from 14 HCC ascites samples, collected from 7 patients before and after treatment with the combination of sintilimab (anti-PD-1) and bevacizumab (anti-VEGF).<h4>Results</h4>We identify a widespread convergence on interferon (IFN) signaling across various immune cell lineages in treatment-responsive patients with HCC, indicating a co2024-01-01T00:00:00Z2024 Nov2026-06-01T12:50:15.712Z2025-04-04T01:20:00.541ZS-EPMC115908413958170610.1136/jitc-2024-010534